Premium
Management of immunotherapy colitis: Special considerations in the COVID‐19 era
Author(s) -
Grover Shilpa,
Bond Sheila A.,
Mansour Michael K.,
Friedman Sonia
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.33125
Subject(s) - medicine , colitis , covid-19 , immunotherapy , pandemic , inflammatory bowel disease , intensive care medicine , disease , coronavirus , cancer , immunology , immune system , virology , infectious disease (medical specialty) , outbreak
The evaluation and management of patients with cancer with suspected immune checkpoint inhibitor (ICI) colitis have distinct challenges within the setting of the coronavirus disease 2019 (COVID‐19) pandemic. The approach to the treatment of patients with ICI colitis requires consideration of the risks and benefits of individual immunosuppressive medications and varies based on the presence of a concurrent COVID‐19 infection.